198 related articles for article (PubMed ID: 38706775)
21. Impact of interstitial lung abnormality on survival after adjuvant durvalumab with chemoradiotherapy for locally advanced non-small cell lung cancer.
Kashihara T; Nakayama Y; Okuma K; Takahashi A; Kaneda T; Katagiri M; Nakayama H; Kubo Y; Ito K; Nakamura S; Takahashi K; Inaba K; Murakami N; Saito T; Okamoto H; Itami J; Kusumoto M; Ohe Y; Igaki H
Radiother Oncol; 2023 Mar; 180():109454. PubMed ID: 36640944
[TBL] [Abstract][Full Text] [Related]
22. Effect of durvalumab on local control after concurrent chemoradiotherapy for locally advanced non-small cell lung cancer in comparison with chemoradiotherapy alone.
Abe T; Saito S; Iino M; Aoshika T; Ryuno Y; Ohta T; Igari M; Hirai R; Kumazaki Y; Miura Y; Kaira K; Kagamu H; Noda SE; Kato S
Thorac Cancer; 2021 Jan; 12(2):245-250. PubMed ID: 33289347
[TBL] [Abstract][Full Text] [Related]
23. Durvalumab Consolidation After Chemoradiotherapy in Elderly Patients With Unresectable Stage III NSCLC: A Real-World Multicenter Study.
Park JE; Hong KS; Choi SH; Lee SY; Shin KC; Jang JG; Kwon YS; Park SH; Choi KJ; Jung CY; Eom JS; Kim S; Seol HY; Kim J; Kim I; Park JH; Kim TH; Ahn JH
Clin Lung Cancer; 2024 Jun; 25(4):354-364. PubMed ID: 38503590
[TBL] [Abstract][Full Text] [Related]
24. Durvalumab in combination with chemoradiotherapy for patients with unresectable stage III non-small-cell lung cancer: Results from the phase 1 CLOVER study.
Kim DW; Chul Cho B; Pachipala K; Kim SW; Wang CL; Chang GC; Ahn MJ; Alvarez R; Chiu CH; Trigo J; Estival A; Karam SD; O'Brien C; Gowda H; Jiang H; Bauman JE
Lung Cancer; 2024 Apr; 190():107530. PubMed ID: 38471416
[TBL] [Abstract][Full Text] [Related]
25. Immunotherapy in unresectable stage III non-small-cell lung cancer: state of the art and novel therapeutic approaches.
Cortiula F; Reymen B; Peters S; Van Mol P; Wauters E; Vansteenkiste J; De Ruysscher D; Hendriks LEL
Ann Oncol; 2022 Sep; 33(9):893-908. PubMed ID: 35777706
[TBL] [Abstract][Full Text] [Related]
26. Current status and progress of concurrent chemoradiotherapy in patients with locally advanced non-small cell lung cancer prior to the approval of durvalumab.
Fukui T; Hosotani S; Soda I; Ozawa T; Kusuhara S; Kakegawa MI; Kasajima M; Hiyoshi Y; Igawa S; Yokoba M; Mitsufuji H; Kubota M; Katagiri M; Sasaki J; Ishiyama H; Naoki K
Thorac Cancer; 2020 Apr; 11(4):1005-1014. PubMed ID: 32057187
[TBL] [Abstract][Full Text] [Related]
27. Patients with unresectable stage III non-small cell lung cancer eligible to receive consolidation therapy with durvalumab in clinical practice based on PACIFIC study criteria.
Sakaguchi T; Ito K; Furuhashi K; Nakamura Y; Suzuki Y; Nishii Y; Taguchi O; Hataji O
Respir Investig; 2019 Sep; 57(5):466-471. PubMed ID: 31104989
[TBL] [Abstract][Full Text] [Related]
28. Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer.
Antonia SJ; Villegas A; Daniel D; Vicente D; Murakami S; Hui R; Yokoi T; Chiappori A; Lee KH; de Wit M; Cho BC; Bourhaba M; Quantin X; Tokito T; Mekhail T; Planchard D; Kim YC; Karapetis CS; Hiret S; Ostoros G; Kubota K; Gray JE; Paz-Ares L; de Castro Carpeño J; Wadsworth C; Melillo G; Jiang H; Huang Y; Dennis PA; Özgüroğlu M;
N Engl J Med; 2017 Nov; 377(20):1919-1929. PubMed ID: 28885881
[TBL] [Abstract][Full Text] [Related]
29. Beyond chemoradiotherapy: improving treatment outcomes for patients with stage III unresectable non-small-cell lung cancer through immuno-oncology and durvalumab (Imfinzi®▼, AstraZeneca UK Limited).
Patel P; Alrifai D; McDonald F; Forster M;
Br J Cancer; 2020 Dec; 123(Suppl 1):18-27. PubMed ID: 33293672
[TBL] [Abstract][Full Text] [Related]
30. Durvalumab for patients with unresectable stage III non-small cell lung cancer and grade 1 radiation pneumonitis following concurrent chemoradiotherapy: a multicenter prospective cohort study.
Sugimoto T; Fujimoto D; Sato Y; Tamiya M; Yokoi T; Tamiya A; Iwasawa S; Hata A; Uchida J; Fukuda Y; Hara S; Kanazu M; Hirano K; Kokubo M; Yamamoto N
Invest New Drugs; 2021 Jun; 39(3):853-859. PubMed ID: 33405089
[TBL] [Abstract][Full Text] [Related]
31. Nationwide Real-Life Safety and Treatment Exposure Data on Durvalumab After Concurrent Chemoradiotherapy in Unresectable Stage III, Locally Advanced, Non-small Cell Lung Cancer: Analysis of Patients Enrolled in the French Early Access Program.
Avrillon V; Daniel C; Boisselier P; Le Péchoux C; Chouaid C
Lung; 2022 Feb; 200(1):95-105. PubMed ID: 35141799
[TBL] [Abstract][Full Text] [Related]
32. Immunotherapy (excluding checkpoint inhibitors) for stage I to III non-small cell lung cancer treated with surgery or radiotherapy with curative intent.
Zhu J; Li R; Tiselius E; Roudi R; Teghararian O; Suo C; Song H
Cochrane Database Syst Rev; 2017 Dec; 12(12):CD011300. PubMed ID: 29247502
[TBL] [Abstract][Full Text] [Related]
33. Patient-reported outcomes with durvalumab after chemoradiotherapy in stage III, unresectable non-small-cell lung cancer (PACIFIC): a randomised, controlled, phase 3 study.
Hui R; Özgüroğlu M; Villegas A; Daniel D; Vicente D; Murakami S; Yokoi T; Chiappori A; Lee KH; de Wit M; Cho BC; Gray JE; Rydén A; Viviers L; Poole L; Zhang Y; Dennis PA; Antonia SJ
Lancet Oncol; 2019 Dec; 20(12):1670-1680. PubMed ID: 31601496
[TBL] [Abstract][Full Text] [Related]
34. Sugemalimab versus placebo after concurrent or sequential chemoradiotherapy in patients with locally advanced, unresectable, stage III non-small-cell lung cancer in China (GEMSTONE-301): interim results of a randomised, double-blind, multicentre, phase 3 trial.
Zhou Q; Chen M; Jiang O; Pan Y; Hu D; Lin Q; Wu G; Cui J; Chang J; Cheng Y; Huang C; Liu A; Yang N; Gong Y; Zhu C; Ma Z; Fang J; Chen G; Zhao J; Shi A; Lin Y; Li G; Liu Y; Wang D; Wu R; Xu X; Shi J; Liu Z; Cui N; Wang J; Wang Q; Zhang R; Yang J; Wu YL
Lancet Oncol; 2022 Feb; 23(2):209-219. PubMed ID: 35038429
[TBL] [Abstract][Full Text] [Related]
35. Phase II Study of Immunotherapy With Tecemotide and Bevacizumab After Chemoradiation in Patients With Unresectable Stage III Non-Squamous Non-Small-Cell Lung Cancer (NS-NSCLC): A Trial of the ECOG-ACRIN Cancer Research Group (E6508).
Patel JD; Lee JW; Carbone DP; Wagner H; Shanker A; de Aquino MTP; Horn L; Johnson ML; Gerber DE; Liu JJ; Das MS; Al-Nsour MA; Dakhil CSR; Ramalingam S; Schiller JH
Clin Lung Cancer; 2020 Nov; 21(6):520-526. PubMed ID: 32807654
[TBL] [Abstract][Full Text] [Related]
36. Long-term survival of locally advanced stage III non-small cell lung cancer patients treated with chemoradiotherapy and perspectives for the treatment with immunotherapy.
Vrankar M; Stanic K
Radiol Oncol; 2018 Feb; 52(3):281-288. PubMed ID: 30210037
[TBL] [Abstract][Full Text] [Related]
37. Radiotherapy Patterns of Care for Locally-advanced Non-small Cell Lung Cancer in the Pre- and Post-durvalumab Era: A Region-wide Survey in a Japanese Prefecture.
Kubo N; Kobayashi D; Iwanaga M; Matsuura M; Higuchi K; Eishima J; Muramatsu H; Okano N; Shioya M; Onishi M; Aoki T; Oike T; Ohno T;
J Radiat Res; 2022 Mar; 63(2):264-271. PubMed ID: 34970980
[TBL] [Abstract][Full Text] [Related]
38. Durvalumab after definitive chemoradiotherapy in locally advanced unresectable non-small cell lung cancer (NSCLC): Real-world data on survival and safety from the German expanded-access program (EAP).
Faehling M; Schumann C; Christopoulos P; Hoffknecht P; Alt J; Horn M; Eisenmann S; Schlenska-Lange A; Schütt P; Steger F; Brückl WM; Christoph DC
Lung Cancer; 2020 Dec; 150():114-122. PubMed ID: 33126091
[TBL] [Abstract][Full Text] [Related]
39. Real-world experience of consolidation durvalumab after concurrent chemoradiotherapy in stage III non-small cell lung cancer.
Huang Y; Zhao JJ; Soon YY; Wong A; Aminkeng F; Ang Y; Asokumaran Y; Low JL; Lee M; Choo JRE; Chan G; Kee A; Tay SH; Goh BC; Soo RA
Thorac Cancer; 2022 Nov; 13(22):3152-3161. PubMed ID: 36177913
[TBL] [Abstract][Full Text] [Related]
40. Phase II Study of Durvalumab Immediately after Completion of Chemoradiotherapy in Unresectable Stage III Non-small Cell Lung Cancer: TORG1937 (DATE Study).
Nakamichi S; Kubota K; Misumi T; Kondo T; Murakami S; Shiraishi Y; Imai H; Harada D; Isobe K; Itani H; Takata S; Wakui H; Misumi Y; Ikeda S; Asao T; Furuya N; Hosokawa S; Kobayashi Y; Takiguchi Y; Okamoto H
Clin Cancer Res; 2024 Mar; 30(6):1104-1110. PubMed ID: 38165684
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]